Neopharma Receives Approval From UAE Ministry of Health to Manufacture H1N1 Medicine

By Prne, Gaea News Network
Sunday, September 27, 2009

DUBAI, UAE - Neopharma, the Abu Dhabi-based pharmaceuticals manufacturer, today announced it has received clearance from the UAE Ministry of Health for the production of an antiviral medication Oseltamivir BR Flu.

The approval comes at a time when the entire region is stepping up efforts to tackle the H1N1 pandemic. The drug is a potential choice to prevent and treat H1N1 flu in the region.

His Excellency Abdulla Humaid Al Mazroei, Vice-Chairman, Neopharma, and Dr. B.R. Shetty, Managing Director and CEO, thanked the UAE Ministry of Health on behalf of the Board of Directors of the company.

Dr. Shetty said: “The endorsement for the antiviral drug to be manufactured by Neopharma reflects the strong support of the Ministry of Health for the vision of the UAE leadership to create a self-sustaining community. As a leading manufacturer of life-saving drugs, we believe it is our responsibility to play a vital role in helping the community at this critical juncture.

“We are confident the approval for Oseltamivir will significantly facilitate medical professionals and the wider community to effectively combat the lethal H1N1 virus in the region.”

Neopharma’s Oseltamivir BR Flu is the outcome of a joint venture with leading pharmaceuticals major Hetero Drugs Ltd and is the first in a series of major life-saving drugs the company plans to produce over the next few years.

Currently, Neopharma has independent production blocks for the manufacture of general and betalactam products. The company’s plant in Abu Dhabi is designed for the large-scale production of tablets, capsules and liquid orals.

About Neopharma:

Neopharma is a premier pharmaceuticals manufacturing company based in Abu Dhabi. Set up in October 2003, Neopharma manufactures a wide range of products including antibiotics, analgesics, respiratory medicines, antihistamines, as well as medications for cardiovascular conditions and diabetes. A robust R&D centre, hi-tech manufacturing and quality embedded operations make the company a manufacturer of world-class pharmaceutical products.

Neopharma has received the prestigious Mohammed bin Rashid Al Maktoum Award in the manufacturing category and is also the recipient of the current European Good Manufacturing Practice Guidelines Certification from Belgium. The company has received the ISO 9001, ISO 14,001 and OHSAS 18,001 certifications for integrated management system encompassing quality, environment and safety standards.

For further information, please call: Zeba Ahmad JiWin Tel: +9714-361-3590 e-mail: Zeba.Ahmad@jiwin.ae

Source: Neopharma

For further information, please call: Zeba Ahmad, JiWin, Tel: +9714-361-3590, e-mail: Zeba.Ahmad at jiwin.ae

YOUR VIEW POINT
NAME : (REQUIRED)
MAIL : (REQUIRED)
will not be displayed
WEBSITE : (OPTIONAL)
YOUR
COMMENT :